Lipid nanoparticles (SLN, NLC, LDC) for the enhancement of oral absorption

Modified-Release Drug Delivery Technology, Second Edition

Volumn 1, Issue , 2008, Pages 269-286

  Keck, Cornelia M ^a   Hommoss, Aiman H ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961638243     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A, et al. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2005; 2(1): 9-22.
2. Chopra S, Mahdi S, Kaur J, et al. Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. J Pharm Pharmacol 2006; 58(8): 1021-32.
3. Kulvanich P, Stewart PJ. The effect of particle size and concentration on the adhesive characteristics of a model drug-carrier interactive system. J Pharm Pharmacol 1987; 39(9): 673-8.
4. Müller RH. Nanosuspensionen-eine neue Formulierung für schwerlösliche Arzneistoffe. In Müller RH, Hildebrand, GE, eds. Pharmazeutische Technologie:Moderne Arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1998:393-400.
5. Möschwitzer J, Müller RH. Drug nanocrystals-the universal formulation approach for poorly soluble drugs. In: Thassu D, Deleers M, Pathak Y, eds. Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. Informa Healthcare, 2007. Adv Drug Deliv Rev 59(6):419-26.
6. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles, in United States Patent 5,145,684. 1992, Sterling Drug Inc. (New York, NY): USA.
7. List M, Sucker H. Pharmaceutical colloidal hydrosols for injection, in GB Patent 2200048. 1988, Sandoz LTD.CH: GB.
8. Sucker H, Gassmann P. Improvements in pharmaceutical compositions, in GB Patent 2269536A. 1994, Sandoz LTD.CH: GB.
9. Violante MR, Fischer HW. Method for making uniformly-sized particles from insoluble compounds, in United States Patent 4,997,454. 1991, The University of Rochester: USA.
10. Müller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. in United States Patent 5,858,410. 1999: USA.
11. Müller RH, Junghanns JU. Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs. In: Torchilin VP, ed. Nanoparticulates as Drug Carriers. London: Imperial College Press, 2006: 307-28.
12. Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 1996; 85(5): 525-9.
13. Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 2001; 50(Suppl. 1): S127-47.
14. Kossena GA, Boyd BJ, Porter CJ, et al. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly watersoluble drugs. J Pharm Sci 2003; 92(3): 634-48.
15. Sek L, Porter CJ, Charman WN. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J Pharmaceut Biomed 2001; 25(3-4): 651-61.
16. Sek L, Porter CJ, Kaukonen AM, et al. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol 2002; 54(1): 29-41.
17. Vine DF, et al. Effect of dietary fatty acids on the intestinal permeability of marker drug compounds in excised rat jejunum. J Pharm Pharmacol 2002; 54(6): 809-19.
18. Charman WN, Rogge MC, Boddy AW, et al. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 1993; 33(4): 381-6.
19. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and longchain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000; 89(8): 1073-84.
20. Reymond JP. In vitro/in vivo Modelle zur Absorption von Ciclosporin A. Dissertation, 1986.
21. Reymond JP, Sucker H, Vonderscher J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm Res 1988; 5(10): 677-9.
22. Reymond JP, Sucker H. In vitro model for ciclosporin intestinal absorption in lipid vehicles. Pharm Res 1988; 5(10): 673-6.
23. Meinzer A, Müller E, Vonderscher J. Perorale Microemulsionsformulierung-Sandimmun Optoral®/Neoral®. In: Müller RH, Hildebrand, GE, eds. Pharmazeutische Technologie: Moderne Arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1998: 169-77.
24. Armand M, Borel P, Pasquier B, et al. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol 1996; 271(1 Pt 1): G172-83.
25. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113(1-3): 151-70.
26. Olbrich C, Muller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 1999; 180(1): 31-9.
27. Virgil, The Aeneid. appr. 29-19 AC.
28. Cavalli R, Bargoni A, Podio V, et al. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92(5): 1085-94.
29. Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41(1): 62-9.
30. Lucks JS, Müller RH. Medication vehicles made of solid lipid particle (solid lipid nanospheres-SLN), in EP0000605497. 1996, Medac: EP.
31. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution, in US Patent US 5,250, 236. 1993: USA.
32. Müller RH, Souto EB, Göppert T, et al. Production of biofunctionalized solid lipid nanoparticles (SLN) for site-specific drug delivery. In: Kumar C, ed. Nanotechnologies for the Life Science. Weinheim: Wiley-VCH Verlag GmbH, 2007: 287-303.
33. Dingler A. Feste Lipid-Nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation. PhD thesis, 1998.
34. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Inte J Pharm 1996; 129: 59-73.
35. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59(6): 478-90.
36. Almeida AJ, Runge S, Müller RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 1997; 149(2): 255-65.
37. Müller RH, Olbrich C. Arzneistoffträger zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoff-Konjugaten (LAK-Partikel), in EPN 0001176984. 2007, PharmaSol GmbH.
38. Olbrich C, Gebner A, Kayser O, et al. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug Diminazenediaceturate. J Drug Target 2002; 10(5): 387-96.
39. Penkler LJ, Muller RH, Runge SA, Ravelli V. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. in United States Patent 6,551,619. 2003, Pharmatec International S.R.L.: USA.
40. Muller RH, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006; 317(1): 82-9.
41. He J, Hou SX, Feng JF, et al. Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles. Zhongguo Zhong Yao Za Zhi 2005; 30(21): 1651-3.
42. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006, 61(5):375-86.
43. Pedersen N, Hansen S, Heydenreich AV, et al. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm 2006; 62(2): 155-62.
44. Hu FQ, Wu MZH, Yuan H, et al. A novel preparation of solid lipid nanoparticles with cyclosporin A for prolonged drug release. Pharmazie 2004; 59(9): 683-5.
45. Hanafy A, Spann-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 2007; 59(6): 419-26.
46. Muchow M, Despatova N, Schmitz E, et al. Nanostructured lipid carriers (NLC) containing fish oil as food supplement. In: 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. 27th-30th March 2006. Geneva.
47. Daubresse JC, Sternon J. Omega-3 fatty acids and cardiovascular diseases. Rev Med Brux 2006; 27(1): 43-8.
48. Engler MM, Engler MB. Omega-3 fatty acids: role in cardiovascular health and disease. J Cardiovasc Nurs 2006; 21(1): 17-24, quiz 25-6.
49. Vahedi K, Atlan P, Joly F, et al. A 3-month double-blind randomised study comparing an olive oil-with a soyabean oil-based intravenous lipid emulsion in home parenteral nutrition patients. Br J Nutr 2005; 94(6): 909-16.
50. n-3 Fatty Acids: Recommendations for Therapeutics and Prevention. Proceedings of a symposium, New York, New York, USA, May 21, 2005. Am J Clin Nutr, 2006. 83(Suppl. 6):1451S-1538S.
51. Black HS, Rhodes LE. The potential of omega-3 fatty acids in the prevention of non-melanoma skin cancer. Cancer Detect Prev 2006; 30(3): 224-32.
52. Bougnoux P, Menanteau J. Dietary fatty acids and experimental carcinogenesis. Bull Cancer 2005; 92(7): 685-96.
53. Hannon K. Have a daily dose of Omega-3. US News World Rep 2005; 139(24): 54-5.
54. Muchow M, Schmitz E, Despatova N, et al. Omega-3 fatty acid-loaded lipid nanoparticles as oral food supplement. In: AAPS Annual Meeting and Exposition. 5th-10th November 2005. Nashville.
55. Muchow M. Nanostructured Lipid Carrier (NLC) for Oral Administration. PhD thesis 2008 (in preparation).
56. Trotta M, Cavalli R, Carlotti ME, et al. Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique. Int J Pharm 2005; 288(2): 281-8.
57. Battaglia L, Trotta M, Gallarate M, et al. Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: development and influence on insulin stability. J Control Release 2007; 24(7): 672-84.
58. Pinto JF, Müller RH. Pellets as carriers of “solid lipid nanoparticles” (SLN) for oral administration of drugs. Eur J Pharm Biopharm 1996; 42: 35.
59. Pinto JF, Müller RH. Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of drugs. Die Pharmazie 1999; 54: 506-9.
60. Bangham AD, Haydon DA. Ultrastructure of membranes: biomolecular organization. Brit Med Bull 1968; 24(2): 124-6.
61. Diederichs JE, Müller RH. Liposome in Kosmetika und Arzeimitteln. Die Pharmazeutische Industrie 1994; 56(3): 267-75.
62. Müller RH. Solid lipid nanoparticles, nanosuspensions and liposomes for pharmaceutical and cosmetic applications. In Diederichs JE, Müller RH, eds. Future Strategies for Drug Delivery with Particulate Systems. Boca Raton:CRC Press, 1998: 71-2.
63. Baum P. R&D-key to the future. Boehringer Ingelheim GmbH, Corporate Division Communications. 2003, Ulm: Sueddeutsche Verlagsgesellschaft. 58.